• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Welldoc gets FDA nod for CGM-guided insulin bolus dosing software

August 23, 2023 By Sean Whooley

Welldoc BlueStar diabetes management platform
The BlueStar platform. [Image from Welldoc]
Welldoc announced today that it won the 11th FDA 510(k) clearance for its BlueStar digital diabetes management platform.

The clearance comes just a week after BlueStar received its 10th FDA clearance for using connected insulin dosing data in personalized bolus insulin dosing recommendations. Welldoc’s newest clearance enables BlueStar to provide bolus insulin dose recommendations based on continuous glucose readings.

BlueStar can now offer dose recommendations based on the most recent glucose reading and rate of change from a compatible CGM. This feature enhances BlueStar’s existing digital coaching capabilities for guiding dietary and lifestyle decisions in diabetes management.

Welldoc said in a news release that this makes it the first company to receive clearance for a CGM-informed bolus calculator of this kind. The company designed it for adults who manage diabetes with multiple daily injections (MDI) of insulin.

“This 11th 510(k) clearance is a remarkable achievement for Welldoc and demonstrates our steadfast commitment to transforming chronic care,” said Kevin McRaith, Welldoc president and CEO. “We are dedicated to creating new digital health capabilities which leverage the latest innovations like CGM to develop more connected and personalized solutions for individuals with complex health needs.”

Welldoc’s last FDA clearance for BlueStar — its ninth in total — expanded insulin dosing support to most types of insulin. That included bolus and premixed insulin titration for type 2 diabetes. That regulatory victory came in September 2021. Previous FDA clearances include in June 2020 when the FDA cleared the BlueStar Insulin Adjustment Program for basal insulin titration. It also holds clearances for advanced AI capabilities and enhanced product features.

More about the Welldoc BlueStar platform

BlueStar, the flagship product from Welldoc, guides individuals through their management of diabetes. It enables self-management of care while enhancing connections to the user’s healthcare team. Welldoc partners with health plans, systems and employers to extend care, improve health and reduce costs.

The platform utilizes AI to leverage health data to bring many dimensions of diabetes care into one platform.

Welldoc partners with health plans, systems and employers aiming to extend care, improve health and reduce costs. The company sees continued CGM adoption in the diabetes space as a way to enhance functionality with its own platform. It said this will help organizations who support diabetes populations provide extended management services and care.

“A device providing insulin therapy adjustments based on CGM inputs must meet specific requirements to be cleared under the 510(k) program, a higher bar than a calculator using blood glucose meter readings alone,” said Ian Cadieux, head of regulatory affairs at Welldoc. “The Welldoc team rose to the occasion, showcasing their capabilities to satisfy these special controls, which include demonstrating clinical validity, cybersecurity, useability and effective risk mitigation.”

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Patient Monitoring, Regulatory/Compliance, Technology Tagged With: FDA, welldoc

IN CASE YOU MISSED IT

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Study backs Tandem automated insulin delivery in pregnant women with type 1 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Abbott could pave new roads in diabetes management with dual sensor on the horizon

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS